Geneva, Switzerland (PRWEB) April 19, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today the Company’s Chief Technology Officer, Armelle Gaussin, PhD, will be speaking on Rapidly Identifying Relevant Monoclonal Antibody Variants at the 2011 PEGS Summit on Wednesday, May 11, 2011, at the Sheraton Boston Hotel in Boston, Massachusetts. Selexis will also be exhibiting at the conference, May 9 – 13, 2011.
Dr. Gaussin’s lecture, “Exploiting Potent Chromatin Remodeling Elements to Rapidly Identify RelevantMonoclonal Antibody Variants in Stable CHO Cell Lines” is part of the Antibody Discovery Strategies and Tools track. Conference attendees can hear Dr. Gaussin’s lecture on Wednesday, May 11 at 11:10 AM.$
Lecture Abstract:
DNA vectors incorporating versatile epigenetic regulatory elements such as the Selexis Genetic Elements (SGEs) provide high transcription rates and prevent transgene silencing, yielding cell clones with increased and stable expression. Thus, combined with optimized gene transfer methods, these vectors can be used to generate high-producer stable cell lines in short time frames and with little screening efforts. This unique feature opens up the possibility of relying on a single stable expression system throughout the drug development process, allowing the identification of relevant monoclonal antibody variants and high expressing clones at the same time. This novel setup allows considerable time and labour saving by screening top lead candidates in a production-ready platform.
Additionally, conference attendees can meet Selexis representatives at Booth 408, May 9 – 13.
To schedule meetings in advance, please contact Selexis at info@selexis.com
Registration for the PEGS conference is required. For more information, visit http://www.pegsummit.com/
